
Join to View Full Profile
20 Duke Medical CtrDurham, NC 27710
Phone+1 919-613-1909
Dr. Muzaffar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- SSM St Mary's Hospital-St LouisResidency, Internal Medicine, 2007 - 2010
- Maulana Azad Medical CollegeClass of 1999
- University of FloridaFellowship, Hematology and Medical Oncology
Certifications & Licensure
- NC State Medical License 2023 - 2025
- FL State Medical License 2014 - 2024
- AR State Medical License 2010 - 2017
- GA State Medical License 2012 - 2016
- MO State Medical License 2007 - 2010
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsCabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2025-02-18 - 2 citationsNemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20 - 1 citationsAuthor Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.Nabil F Saba, Conor E Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca
Nature Medicine. 2024-08-01
Press Mentions
- Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: